FBRX vs. BNTC, CMRX, IOBT, TLSA, VTVT, ASMB, ONCY, PYRGF, ANVS, and SLS
Should you be buying Forte Biosciences stock or one of its competitors? The main competitors of Forte Biosciences include Benitec Biopharma (BNTC), Chimerix (CMRX), IO Biotech (IOBT), Tiziana Life Sciences (TLSA), vTv Therapeutics (VTVT), Assembly Biosciences (ASMB), Oncolytics Biotech (ONCY), PyroGenesis Canada (PYRGF), Annovis Bio (ANVS), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical preparations" industry.
Benitec Biopharma (NASDAQ:BNTC) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.
Benitec Biopharma has higher revenue and earnings than Forte Biosciences. Benitec Biopharma is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 4.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 10.5% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Benitec Biopharma received 156 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 63.73% of users gave Benitec Biopharma an outperform vote while only 56.82% of users gave Forte Biosciences an outperform vote.
Benitec Biopharma's return on equity of -99.44% beat Forte Biosciences' return on equity.
Benitec Biopharma currently has a consensus target price of $16.00, suggesting a potential upside of 81.41%. Forte Biosciences has a consensus target price of $2.75, suggesting a potential upside of 391.07%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Benitec Biopharma.
Benitec Biopharma has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
In the previous week, Benitec Biopharma and Benitec Biopharma both had 2 articles in the media. Forte Biosciences' average media sentiment score of 1.88 beat Benitec Biopharma's score of 1.55 indicating that Benitec Biopharma is being referred to more favorably in the media.
Summary
Benitec Biopharma and Forte Biosciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Forte Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Forte Biosciences Competitors List
Related Companies and Tools
